Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Authors:
- M. R. JacobsMJM. R. Jacobs
- P. C. AppelbaumPAP. C. Appelbaum
Open Access
- 1 June 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 39 (suppl 2) , 23-27
Abstract
A time-kill method was developed to examine the killing kinetics of trovafloxacin, ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against one strain each of Bacteroides fragilis, Bacteroides thetaiotaomicron, Prevotella melaninogenica, Fusobacterium mortiferum, Peptostreptococcus magnus and Clostridium perfringens. Solutions and suspensions were prepared inside an anaerobic glove box, using syringes and prereduced broth. Bottles were then incubated outside the chamber and viability counts determined after incubation for 0, 6, 24 and 48 h in a shaking water bath, avoiding introduction of air. Bacteriostatic/bactericidal concentrations (mg/L) after 48 h for the six strains were: trovafloxacin, 0.03-1/0.03-1; ciprofloxacin, 0.25-16/0.25-32; sparfloxacin, 0.06-2/0.06-8; metronidazole 1-64/1-64; cefoxitin, 0.125-16/0.125-32; piperacillin, 0.125-64/0.125-64; piperacillin/tazobactam, 0.06-2/0.125-8. Bacteriostatic levels were within two dilutions of broth MICs. By this time-kill method, trovafloxacin had the lowest bacteriostatic concentrations of all compounds tested.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteersJournal of Antimicrobial Chemotherapy, 1995
- Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycinAntimicrobial Agents and Chemotherapy, 1994
- Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactamJournal of Antimicrobial Chemotherapy, 1993
- Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacinJournal of Antimicrobial Chemotherapy, 1993
- Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfioxacin, tosufloxacin, CI-960 and CI-990Journal of Antimicrobial Chemotherapy, 1993
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- In vitro activity of CP-74667 compared with four other fluoroquinolonesDiagnostic Microbiology and Infectious Disease, 1992
- Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1992
- In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacinAntimicrobial Agents and Chemotherapy, 1991